Previous clinical studies showed that prostate-specific antigen (PSA) plays an important tumor marker for prostate cancer in male and nandrolone phenpropionate is an androgen receptor agonist and previous study showed that it can decrease cell growth of prostate cancer LNCaP cells [46]. This evidence concerns the gene AR and neoplasm.